The National Ataxia Foundation and the National Fragile X Foundation are excited to partner on a webinar series about FXTAS! Do you or a loved one have a FXTAS? Dr. David Hessl will teach us how Fragile X-associated tremor/ataxia syndrome (FXTAS) is studied and give an overview of the current state of research and drug development for the disease.
The National Ataxia Foundation and the National Fragile X Foundation are excited to partner on a webinar series about FXTAS! Do you or a loved one have a Fragile X-associated tremor/ataxia syndrome (FXTAS)? Join our webinar to learn about the mechanisms of the disease, the diagnostic journey, and what to expect for clinical care with this diagnosis.
Drs. Deborah Hall and Peter Todd joined us for an informative webinar on the topic of Fragile X-associated Tremor/Ataxia syndrome (FXTAS).
This is the first time that Fragile X premutation carriers have been tracked in a longitudinal study. This study provides evidence for early markers of FXTAS that may be helpful in eventually identifying the best candidates for early, preventive intervention.
The first published publication from the International Fragile X Premutation Registry Advisory Committee. This International Fragile X Premutation Registry is an important first step and can serve as a useful tool for clinicians and researchers in the field.
Rush University is conducting a research study to validate a rating scale created to assess the motor symptoms of people with FXTAS – the “Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)”
On May 5, 2022, The Wall Street Journal Weekend Edition showcased an article called “The Surprising Legacy of a Genetic Disorder” by Dr. Anne Skomorowsky. The essay summarizes the history of Fragile X and [...]
Thanks to The European Fragile X Network, FMR1 now stands for fragile X messenger ribonucleoprotein 1, removing the reference to “mental retardation” which has long been outdated in common vernacular.
Being able to identify and diagnose possible nervous system disorders by detecting gait problems 15 to 20 years before their clinical diagnosis could help advance treatment development and quality of life.
This system could potentially predict FXTAS onset in premutation carriers who are not showing signs of FXTAS on a neurological exam.
Fragile X Info Series Fragile X-Associated Tremor/Ataxia Syndrome Statistics, onset, progression, diagnosis, and interventions and treatments for FXTAS, an adult-onset neurological condition, seen primarily in males. ENGLISH [...]
RESEARCH RESULTS ROUNDUP — Investigation into how aging as a premutation carrier of the FMR1 gene may affect sensorimotor (exactly as it sounds, both sensory and motor) brain systems.
The Who, What & How for Genetic CounselingWho Should Seek Out a Genetic Counselor?Anyone who has:Been identified as being a “Fragile X carrier” or has positive, inconclusive, or in any way unusual Fragile X testing [...]
Consensus of the Fragile X Clinical & Research Consortium Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Reading Time: 21 min.—|—Last Updated: June 2021—|—First Published: March 2018—|—English PDF—|—Spanish PDF Introduction TABLE 1. [...]
The Modifiers of Fragile X-Associated Disorders (FX-MOD) study is trying to answer the question, why do some people develop tremor and balance issues and others do not?
